HIVEP3

Across TCGA pan-cancer cohorts, HIVEP3 mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated HIVEP3 data layer compared with 24 for mass-spec protein and 13 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher HIVEP3 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated HIVEP3 expression acts as an unfavorable survival marker.

PDAC, HNSC, and LUAD are the cancer types where HIVEP3 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Median	All	0.330	0.561	.003	26	view →
HNSC	OS	Median	III,IV	0.733	0.968	.016	4	view →
LUAD	DFS	Median	All	0.848	0.934	.045	1	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

HIVEP3–PDAC (DFS)

Open the PDAC breakdown →